Probiotics Ingestion Does Not Directly Affect Thyroid Hormonal Parameters in Hypothyroid Patients on Levothyroxine Treatment

Giorgia Spaggiari1,2, Giulia Brigante1,2*, Sara De Vincentis1,2, Umberto Cattini1, Laura Roli3, Maria Cristina De Santis3, Enrica Baraldi3, Simonetta Tagliavini3, Manuela Varani3, Tommaso Trenti3, Vincenzo Rochira1,2, Manuela Simoni1,2 and Daniele Santi1,2

1 Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy, 2 Unit of Endocrinology, Department of Medicine, Endocrinology, Metabolism and Geriatrics, Azienda Ospedaliero Universitaria di Modena, Modena, Italy, 3 Department of Laboratory Medicine and Pathological Anatomy, Azienda USL of Modena, Modena, Italy

Purpose: The relationship between probiotics and levothyroxine (LT₄) requirement has not yet been investigated. The aim of this study was to assess whether a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®) is able to influence LT₄ metabolism acting on the gut microbiota.

Methods: A prospective, randomized, single-blind, controlled, investigator-started clinical trial was carried out. Patients with primary hypothyroidism were randomly assigned to the study (VSL#3® + LT₄) and the control group (LT₄). A 2-month treatment phase was followed by 2 months of follow-up. Clinical examination, blood tests for thyroid function and for peripheral tissue markers of thyroid hormones (PTM) were performed monthly. LT₄ dose adjustments were performed when necessary.

Results: Thirty-nine patients were enrolled in the study group and 41 in the control group. No difference in thyroid function [thyroid-stimulating hormone (TSH), free triiodothyronine (fT₃), and free thyroxine (fT₄)] and PTM was found between groups and among visits. FT₃/fT₄ ratio was directly correlated to TSH at each visit in both groups, with the exception of the first evaluation of probiotics-treated subjects (rho = 0.287, p = 0.076).

LT₄ daily dose adjustments occurred more frequently in the control than in the study group (p = 0.007), despite no differences in the mean LT₄ daily dose. In particular, LT₄ doses were increased six times in the control group and decreased four times in the study group.

Conclusion: VSL#3® does not directly alter thyroid functional compensation. A probiotics-mediated influence on thyroid hormones homeostasis is suggested since probiotics supplementation could be able to prevent serum hormonal fluctuations.

ClinicalTrials.gov ID: Registration number NCT03095963.

Keywords: levothyroxine, probiotics, VSL#3®, thyroid-stimulating hormone, thyroid hormones, gut microbiota
INTRODUCTION

Levothyroxine (LT₄) is the standard therapeutic choice in hypothyroidism replacement therapy (1). Representing the synthetic equivalent of native tetraiodothyronine (T₄), LT₄ modulates the same biological functions (2). In the literature, several peripheral markers have been proposed to measure the peripheral response to thyroid hormones (THs), such as lipid profile [total cholesterol (CH), low density lipoprotein CH, and lipoprotein(a)], coagulation parameters [plasminogen activator inhibitor], hepatic protein synthesis indexes [sex hormone-binding globulin (SHBG) and ferritin], muscular system (creatine phosphokinase and myoglobin), bone metabolism parameters (osteocalcin and urinary N-telopeptide), and selected enzymatic activity [angiotensin-converting enzyme (ACE) and glucose-6-phosphate dehydrogenase] (2).

LT₄ is administered orally, dissolved by gastric acids and absorbed mainly in jejunum and ileum (1). Many factors influence LT₄ absorption, such as food and beverages (3–5), drugs (6–13), and pathological conditions impairing the digestive tract absorptive ability (7, 14, 15). Moreover, several drugs are able to interfere with TH requirements increasing LT₄ metabolism and clearance (4), or acting on expression and activity of catabolic enzymes (16).

The LT₄ activation and inactivation occur through the action of deiodinases (17). Reversible sulfto transferases and glucuronyltransferases mediate the inactivation of TH in the liver, increasing iodothyronines water-solubility, promoting biliary and urinary clearance (17). In the bowel, gut bacteria expressing β-glucuronidases and sulfatase enzymes are able to hydrolyze glucuronidated and sulfated iodothyronines metabolites (17, 18). In this way, lipophilic deconjugated iodothyronines can be reabsorbed, constituting the enterohepatic recycle of THs (17, 18). According to this mechanism, LT₄ requirement could be regulated acting on intestinal bacteria and modifying THs enterohepatic recycle. In this context, gut can be considered a possible reservoir of THs (17), although a clear in vivo demonstration is still lacking.

Probiotics are defined as live microorganisms which, when consumed in adequate amounts, confer a health effect on the host (19). They are not considered drugs by the current international legislation (19). Probiotics limit the intestinal colonization from pathogenic bacteria (20, 21), improve the physiological bowel barrier function (20, 21), and influence the pro-inflammatory and anti-inflammatory cytokines production (20–23). However, the mechanism by which probiotics contribute to microbiota modulation has not been completely clarified so far (20). Although an effect of probiotics on health has been proposed in several pathologic conditions (18, 20, 24–37), a clear demonstration is still lacking.

Up to now, there is low evidence of probiotics interaction with concomitant drug ingestion, considering their influence on bacteria enzymatic activity (38, 39). Since products containing probiotics are very popular, it would be important to discover any possible interference with pharmacological therapies. This interaction could result in clinical consequences on LT₄-treated patients simultaneously taking probiotics. This is the first clinical trial designed to investigate whether a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®) is able to influence LT₄ metabolism acting on the gut microbiota in hypothyroid patients.

MATERIALS AND METHODS

A prospective, randomized, single-blind, controlled, investigator-started clinical trial was carried out (ClinicalTrials.gov ID: registration number NCT03095963).

Patients’ inclusion criteria were: primary hypothyroidism on LT₄ replacement therapy, thyroid-stimulating hormone (TSH), fT₃, and fT₄, in the normal range, stable LT₄ dosage during the 6 months before enrolment, Caucasian ethnicity, age 18–65 years. Exclusion criteria were total thyroidectomy for thyroid carcinoma, intestinal malabsorption (e.g., bariatric surgery, inflammatory bowel diseases, celiac disease), ongoing therapies interfering with LT₄ absorption and/or metabolism (i.e., aluminum-containing antacids, sucralfate, proton pump inhibitors, calcium carbonate, raloxifene, bile acids sequestrants, and ferrous sulfate), and antibiotics treatment in the 6 months before enrolment.

Study Design

Consecutive patients on LT₄, replacement therapy attending the Endocrinology Unit of Modena (Italy) were screened. According to inclusion and exclusion criteria, 80 participants were enrolled and randomized in study or control group. The random allocation sequence was generated using “Statistical Package for the Social Sciences” software for Macintosh (SPSS) considering a 1:1 ratio by the statistician of the Unit. Clinicians evaluating and enrolling patients were blinded to the randomization list. The study design provided a monthly visit for a 4 months overall time-frame. Patients assigned to the study group took the probiotic supplement VSL#3® for 2 months, followed by a 2-month period of follow-up (Figure 1). All patients were instructed to take LT₄ tablets with water in the morning with empty stomach, at least 30 min before breakfast and/or other medicine ingestion. Study group patients were taught to assume the probiotic supplement at least 2 h after LT₄ administration, irrespective of meals, to dissolve it in a cold beverage and to store it in a refrigerator (2–8°C), in order to preserve bacteria load. Patients assigned to the control group continued their LT₄ therapy without placebo administration.

The study design was single-blind since only the clinician was aware of the allocation. The VSL#3® administration was provided by nurses. Participants were invited to return all used and unused sachets to count the number of opened sachets per the number of treatment days.

All patients underwent five monthly visits (baseline, visit 1, 2, 3, and 4), in which anthropometrical evaluation (weight and height) and hormonal function assessment were performed. A fasting blood sample was taken in the morning at each visit before LT₄ ingestion. Since TSH results were available the same day of blood sampling, LT₄ daily dose was promptly adjusted on occurrence of TSH alterations (laboratory reference range: 0.35–4.94 μIU/mL), according to clinical guidelines (40).
At baseline, visit 2, and visit 4, patients underwent clinical examination with heart rate and blood pressure evaluation (Figure 1). During each visit, the following data were collected: probiotic ingestion, sex, age, hypothyroidism etiology, LT4 formulation dose and brand, body mass index (BMI), body surface area (BSA), systolic blood pressure, diastolic blood pressure, heart rate, TSH, fT4, fT3, and any possible LT4 posology adjustment.

**VSL#3®**

VSL#3® is a multistrain probiotic supplement available in packets. Each VSL#3® sachet contains a high concentration (450 × 10⁹ CFU) of live freeze-dried bacteria, belonging to eight different strains, i.e., *Bifidobacterium breve*, *Bifidobacterium longum*, *Bifidobacterium infantis*, *Lactobacillus acidophilus*, *Lactobacillus plantarum*, *Lactobacillus paracasei*, *Lactobacillus bulgaricus*, and *Streptococcus thermophilus*. The compound was chosen considering its highest concentration among commonly used probiotics-containing products.

**Laboratory Analyses**

During the 4 months evaluation timeline, thyroid function assessment (TSH, fT3, fT4) was performed monthly to revise LT4 dosage if necessary. Blood samples for each patient at each visit were stored at −20°C until the end of enrolment, to measure peripheral tissue markers of THs. Table S1 in Supplementary Material summarizes methodologies used for each assay and the respective intra- and inter-assay coefficient of variation.

**Statistical Analysis**

Considering that no studies so far evaluated the influence of probiotics on hormonal measurements, the sample size was calculated using a previous study aiming at analyzing the influence on LT4 absorption. Singh et al. found a TSH decrease of about 70% after concomitant ingestion of calcium and LT4 in patients treated for hypothyroidism (41). Thus, assuming a similar variation of TSH in patients treated with both probiotics and LT4, using ANOVA univariate statistical analysis, considering a statistical power of 90% and an α-error of 0.05, the required sample size was of 80 patients. Setting a 1:1 case–control ratio, the final sample size was of 40 patients for each group.

Continuous parameters were compared between study and control groups through ANOVA univariate and/or Mann–Whitney test, according to data distribution, evaluated by Kolmogorov–Smirnov test. Categorical variables were compared...
with Chi-square or Fisher exact test. The changes after treatment were evaluated considering repeated variables, using Wilcoxon signed-rank test. The degree of correlation between ordinal variables was studied using Spearman rho correlation test.

In order to evaluate THs metabolism and pituitary feedback, fT₃/fT₄, fT₃/TSH, and fT₄/TSH ratios were calculated. Moreover, hormonal measurements were adjusted for the anthropometrical available variables (BMI and BSA).

Statistical analysis was performed using the “Statistical Package for the Social Sciences” software for Macintosh (version 21.0; SPSS Inc., Chicago, IL, USA). Statistical significance was considered significant when \( p < 0.05 \).

Ethical Approval
The Institutional Review Board of Modena (Comitato Etico di Modena) approved the study (code 184/13, approved on 12th November 2013).

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent
Written informed consent was obtained from all individual participants included in the study.

RESULTS
One hundred and twenty hypothyroid patients on LT₄ replacement therapy were screened and 80 patients were enrolled according to inclusion and exclusion criteria (Figure 2). Thirty-nine patients (48.8%) entered the study group and 41 (51.2%) the control group. Baseline characteristics of patients are shown in Table 1.

At baseline, three male patients (3.75%) entered the study group while no male patients entered the control group. This gender disparity is in line with the known highest female incidence of primary hypothyroidism (1). Three patients (one male and two females) (7.69%) dropped out from the study group and six female patients (14.63%) dropped out from the control group (Figure 2). No adverse events were recorded in both groups and dropouts occurred for patients’ decision.

No differences were observed between study and control group, considering anthropometrical variables (Table 1). Only heart rate was significantly higher in the control than in the study group (\( p = 0.043 \)).

The main cause of hypothyroidism was Hashimoto thyroiditis, occurring with similar incidence both in study and control group (71.8 and 73.2%, respectively; \( p = 0.916 \)). Only two patients (4.88%) in the control group presented an iatrogenic hypothyroidism, due to total thyroidectomy or to radioiodine treatment. The majority of the patients was treated with branded LT₄ (97.5% in both groups; \( p = 0.971 \)) and only the tablet formulation was used. Among branded LT₄, Eutirox® was the mostly taken (94.9% in the study vs. 90.2% in the control group; \( p = 0.432 \)). The remaining patients were treated with Tirosint® (2.6% in the study group vs. 7.3% in the control group; \( p = 0.644 \)).

The calculated compliance for probiotics ingestion was 79.2% in the study group.

Thyroid Hormones
Thyroid-stimulating hormone, fT₃, fT₄ did not change between study and control group at each visit, as well as among visits in the two groups (Table 2). The lack of significance was confirmed after adjustment for BMI and BSA or considering hormonal ratios (fT₃/fT₄, fT₃/TSH, and fT₄/TSH).

In the control group, TSH was inversely related to fT₃, and fT₄ (\( \rho = -0.593, p < 0.001 \) and \( \rho = -0.293, p = 0.004 \), respectively) while fT₃ and fT₄ were directly related each other (\( \rho = 0.269, p = 0.004 \)), as expected according to TH physiology. Unexpectedly, the correlation between TSH and fT₄ was lost after adjustment for age (\( p = 0.377 \)) and BMI (\( p = 0.286 \)). Similarly, TSH was inversely related to fT₃ (\( \rho = -0.547, p < 0.001 \)) in the study group, but their correlation to fT₁ was absent (\( p = 0.516 \) and \( p = 0.462 \), respectively). However, in both groups, the correlation was lost when each visit was considered separately, suggesting that the low number of cases evaluated in subgroup analyses impaired the statistical power.

Regarding anthropometrical features at baseline, TSH was directly related to BMI (\( \rho = 0.227, p = 0.047 \), but not to BSA (\( \rho = 0.167, p = 0.146 \)). Accordingly, fT₃, was inversely related to BMI (\( \rho = -0.260, p = 0.023 \)), while fT₄ did not correlate with any anthropometrical variable. Moreover, a direct correlation between TSH serum levels and systolic and diastolic pressures was found (\( \rho = 0.282, p = 0.012 \) and \( \rho = 0.227, p = 0.046 \), respectively). On the contrary, neither fT₃, nor fT₄, correlated with blood pressure. Similarly to what obtained for hormonal data, these relationships were lost considering following visits. Moreover, heart rate did not correlate to THs at any time point.

Evaluating the peripheral conversion of TH, the fT₃/fT₄ ratio was directly related to TSH at each visit in the control group, as expected for the known feedback mechanism. In the study group, this correlation was lost at visit 1 (\( \rho = 0.287, p = 0.076 \)), after
one month of probiotics treatment, suggesting a possible probiotics effect on this central pathway.

**LT₄ Dose Adjustments**

LT₄ therapy was adjusted 10 times in 8 patients (10% of the total number of patients). In particular, LT₄ doses were increased six times in four patients (the same patient needed three dosage adjustments) in the control group and decreased four times in four different patients in the study group (Table 3). Dose adjustments were performed upon occurrence of alterations of serum TSH levels, as suggested by clinical guidelines (40). Interestingly, LT₄ dose adjustments occurred more frequently in the control than in the study group (p = 0.007). However, the mean LT₄ daily dose did not differ between groups (p = 0.419) and among visits (p = 0.916 in the control group and p = 0.970 in the study group). Considering patients with unchanged LT₄ dose during the trial (90% of the total number of patients), the lack of hormonal changes after probiotic treatment remained.

As expected, LT₄ dose was directly related to fT₃ in the study (rho = 0.299, p = 0.001) and control group (rho = 0.457, p < 0.001), respectively. Moreover, LT₄ dose was inversely related to TSH in the study (rho = −0.448, p < 0.001) and control group (rho = −0.205, p = 0.029), respectively. Considering each visit separately these relationships remained. However, LT₄ dose was not correlated with serum fT₄ levels in any group (study group: rho = −0.041, p = 0.579; control group: rho = −0.079, p = 0.289).

### Table 1: Patients data and characteristics collected at baseline.

| Reference range | Study group | Control group | p Value |
|-----------------|-------------|---------------|---------|
| BMI (kg/m²)     | 18.50–24.99 | 27.77         |         |
| Patients number | 39          | 41            | 0.222   |
| Female, n (%)   | 36 (92.3)   | 41 (100)      |         |
| Male, n (%)     | 3 (7.7)     | 0 (0)         | 0.222   |
| Autoimmune thyroiditis, n (%) | 29 (71.8) | 30 (73.2) | 0.916  |
| Non-autoimmune hypothyroidism, n (%) | 11 (28.2) | 9 (22)  | 0.698  |
| Post-thyroidectomy, n (%) | 0 (0)     | 1 (2.4)       | 0.960   |
| Post radioiodine, n (%) | 0 (0)      | 1 (2.4)       | 0.960   |
| Eutirox®, n (%) | 37 (94.9)   | 37 (90.2)     | 0.718   |
| Autoimmune thyroiditis | 3 (7.7) | 0 (0) | 0.222  |
| Male, n (%)     | 36 (92.3)   | 41 (100)      |         |
| Female, n (%)   | 3 (7.7)     | 0 (0)         | 0.222   |

Data are expressed as mean ± SD. p value is considered significant when p < 0.05.

### Table 2: Thyroid axis hormonal measurements.

| Reference range | Study group | Control group | p Value |
|-----------------|-------------|---------------|---------|
| TSH (μIU/mL)    | 0.35–4.94   |               |         |
| Baseline        | 2.37 ± 1.66 | 2.81 ± 1.88   | 0.308   |
| Visit 1 (treatment phase) | 2.36 ± 1.68 | 2.97 ± 3.38 | 0.565  |
| Visit 2 (treatment phase) | 2.17 ± 1.84 | 3.88 ± 7.57 | 0.344  |
| Visit 3 (follow-up phase) | 2.53 ± 3.08 | 2.84 ± 2.47 | 0.343  |
| Visit 4 (follow-up phase) | 2.23 ± 1.72 | 3.27 ± 4.24 | 0.344  |
| p value         | –           | 0.896         | 0.970   |
| fT₃ (pg/mL)     | 1.7–3.7     |               |         |
| Baseline        | 2.7 ± 0.3   | 2.6 ± 0.3     | 0.871   |
| Visit 1 (treatment phase) | 2.7 ± 0.4   | 2.7 ± 0.3     | 0.894   |
| Visit 2 (treatment phase) | 2.7 ± 0.4   | 2.7 ± 0.3     | 0.759   |
| Visit 3 (follow-up phase) | 2.6 ± 0.4   | 2.7 ± 0.3     | 0.079   |
| Visit 4 (follow-up phase) | 2.7 ± 0.4   | 2.7 ± 0.3     | 0.809   |
| p value         | –           | 0.873         | 0.592   |
| fT₄ (pg/mL)     | 7–15        |               |         |
| Baseline        | 10.8 ± 1.6  | 10.9 ± 1.6    | 0.902   |
| Visit 1 (treatment phase) | 10.9 ± 1.3  | 11.0 ± 1.6   | 0.850   |
| Visit 2 (treatment phase) | 10.9 ± 1.3  | 10.9 ± 1.6   | 0.962   |
| Visit 3 (follow-up phase) | 10.7 ± 1.2  | 10.9 ± 1.6   | 0.820   |
| Visit 4 (follow-up phase) | 10.9 ± 1.6  | 10.7 ± 1.7   | 0.424   |
| p value         | –           | 0.988         | 0.805   |

Data are expressed as mean ± SD. p value is considered significant when p < 0.05.

### Table 3: Distribution of LT₄ dose adjustments among groups.

| LT₄ dose | Study group | Control group |
|---------|-------------|---------------|
| Decrease| 4           | 4             |
| Increase| 6           | 6             |

| LT₄ dose adjustments |
|----------------------|
| All patients         |
| Number of patients   | 4            | 4             | 8             |
| Times of LT₄ dose adjustments | 4            | 6             | 10            |
| Study group          |
| Number of patients   | 4            | 0             | 4             |
| Times of LT₄ dose adjustments | 4            | 0             | 4             |
| Control group        |
| Number of patients   | 0            | 4             | 4             |
| Times of LT₄ dose adjustments | 0            | 6             | 6             |
Peripheral Tissue Markers

All the peripheral tissue markers of THs evaluated did not change between groups or among visits (Table 4).

Considering baseline, TSH was directly related to CH (rho = 0.278, p < 0.001), CK (rho = 0.143, p = 0.007), myoglobin (rho = 0.134, p = 0.010), and ferritin (rho = 0.187, p < 0.001) and inversely to SHBG (rho = −0.160, p = 0.002). FT₃ was inversely related to CH (rho = −0.247, p < 0.001) and myoglobin (rho = −0.112, p = 0.033) and directly to SHBG (rho = 0.211, p < 0.001). FT₄ was inversely related to lipoprotein(a) (rho = −0.185, p < 0.001) and osteocalcin (rho = −0.105, p = 0.045). At visit 2, TSH remained directly related to CH (rho = 0.389, p = 0.017) and inversely to SHBG (rho = −0.326, p = 0.049). Accordingly, FT₃ remained inversely related to CH (rho = −0.372, p = 0.025) and directly to SHBG (rho = 0.443, p = 0.007). These results confirm that CH and SHBG are the most significant tissue effectors of THs action.

Sixty patients were hypercholesterolemic (30 in the study group and 30 in the control group) at baseline, considering the proposed cutoff of CH > 200 mg/dL. Considering only patients with high CH serum levels, peripheral tissue markers did not change among visits and between groups.

Multivariate Analyses

Stepwise multivariate linear analyses were performed considering TSH, FT₃, and FT₄ as dependent variables and anthropometrical parameters as independent. No significant models were generated in any group.

DISCUSSION

Although the beneficial effects of probiotics were demonstrated in several physiopathological conditions, their impact on thyroid function in humans was not evaluated so far. Here, we found that the intake of a probiotic mixture does not alter directly LT₄ therapy compensation in patients with primary hypothyroidism on substitutive treatment. Moreover, the probiotics-induced modification of intestinal bacteria seems to be not able to influence LT₄ absorption when probiotics are administered at least 2 h after LT₄ intake, since no hormonal serum variation was observed. While serum levels of TSH, FT₃, and FT₄ reflect drug absorption, the tissue markers analyzed in this study express THs action at the peripheral level. As a confirmation, no change after probiotics administration was observed. The lack of variation in both circulating hormone levels and THs tissue effect is consistent with the absence of differences in the therapeutic needs between groups and among visits. Nevertheless, a significant difference considering LT₄ adjustments required in the two groups was found. Interestingly, controls needed significantly higher LT₄ dose adjustments in comparison with cases, even if no changes in the mean LT₄ daily dose occurred. We speculate that concomitant probiotics intake could increase the stability in thyroid function compensation. Thus, gut microbiota modification could allow an increased LT₄ bioavailability, drawing from the THs intestinal reservoir through enterohepatic recycle. Indeed, the iodothyronines deconjugation is mediated by bacterial enzymes sulfatases and β-glucuronidases and the VSL#3 action on gut microbiota could

| TABLE 4 | Peripheral tissue markers of thyroid hormones. |
|----------|-----------------------------------------------|
|          | Reference range | Study group | Control group | p Value |
| CH (mg/dL) | <200            |            |              |        |
| Baseline   | 219 ± 30       | 222 ± 37   | 0.626        |
| Visit 1 (treatment phase) | 226 ± 40 | 224 ± 39 | 0.780 |
| Visit 2 (treatment phase) | 213 ± 31 | 214 ± 48 | 0.898 |
| Visit 3 (follow-up phase) | 217 ± 39 | 219 ± 40 | 0.743 |
| Visit 4 (follow-up phase) | 220 ± 27 | 225 ± 45 | 0.582 |
| p value    | –              | 0.496      | 0.853        | –      |
| CK (U/L)   | 10–171         |            |              |        |
| Baseline   | 93 ± 50        | 116 ± 10   | 0.658        |
| Visit 1 (treatment phase) | 77 ± 40 | 98 ± 77 | 0.240 |
| Visit 2 (treatment phase) | 77 ± 38 | 103 ± 75 | 0.085 |
| Visit 3 (follow-up phase) | 115 ± 137 | 107 ± 106 | 0.759 |
| Visit 4 (follow-up phase) | 81 ± 40 | 97 ± 86 | 0.864 |
| p value    | –              | 0.636      | 0.840        | –      |
| Myoglobin (mg/mL) | 15–106 |            |              |        |
| Baseline   | 24 ± 11        | 25 ± 11    | 0.616        |
| Visit 1 (treatment phase) | 21 ± 8  | 23 ± 15   | 0.599        |
| Visit 2 (treatment phase) | 21 ± 6  | 23 ± 8    | 0.165        |
| Visit 3 (follow-up phase) | 23 ± 13 | 24 ± 10  | 0.368        |
| Visit 4 (follow-up phase) | 23 ± 7  | 24 ± 9    | 0.729        |
| p value    | –              | 0.569      | 0.545        | –      |
| Ferritin (mg/mL) | 25–400 |            |              |        |
| Baseline   | 51 ± 61        | 44 ± 27    | 0.102        |
| Visit 1 (treatment phase) | 47 ± 53 | 43 ± 31  | 0.201        |
| Visit 2 (treatment phase) | 41 ± 43 | 47 ± 37  | 0.078        |
| Visit 3 (follow-up phase) | 40 ± 47 | 41 ± 31  | 0.222        |
| Visit 4 (follow-up phase) | 41 ± 41 | 41 ± 27  | 0.202        |
| p value    | –              | 0.992      | 0.881        | –      |
| Lipoprotein(a) (mg/dL) | 1–30 |            |              |        |
| Baseline   | 21 ± 18        | 22 ± 28    | 0.516        |
| Visit 1 (treatment phase) | 21 ± 21 | 20 ± 25   | 0.406        |
| Visit 2 (treatment phase) | 19 ± 18 | 20 ± 25   | 0.547        |
| Visit 3 (follow-up phase) | 19 ± 19 | 17 ± 19   | 0.537        |
| Visit 4 (follow-up phase) | 22 ± 19 | 19 ± 25   | 0.238        |
| p value    | –              | 0.967      | 0.980        | –      |
| Osteocalcin (ng/mL) | 4.6–65.4 | Baseline |              |        |
| Baseline   | 16.0 ± 5.6     | 16.2 ± 5.2 | 0.832        |
| Visit 1 (treatment phase) | 15.4 ± 5.8 | 14.4 ± 6.5 | 0.475      |
| Visit 2 (treatment phase) | 15.1 ± 5.7 | 14.2 ± 7.1 | 0.557      |
| Visit 3 (follow-up phase) | 14.7 ± 6.5 | 14.7 ± 5.2 | 0.990      |
| Visit 4 (follow-up phase) | 14.4 ± 6.0 | 14.7 ± 6.2 | 0.879      |
| p value    | –              | 0.826      | 0.598        | –      |
| ACE (U/L)  | 8–52           |            |              |        |
| Baseline   | 35 ± 13        | 33 ± 15    | 0.551        |
| Visit 1 (treatment phase) | 30 ± 11 | 31 ± 15  | 0.755        |
| Visit 2 (treatment phase) | 31 ± 12 | 29 ± 15  | 0.495        |
| Visit 3 (follow-up phase) | 32 ± 13 | 33 ± 21  | 0.820        |
| Visit 4 (follow-up phase) | 31 ± 12 | 32 ± 15  | 0.668        |
| p value    | –              | 0.361      | 0.751        | –      |
| SHBG (nmol/L) | 19.8–155.2 | Baseline |              |        |
| Female     | 13.5–71.4      | 78.9 ± 57.2 | 71.3 ± 43.1 | 0.981 |
| Visit 1 (treatment phase) | 70.5 ± 45.8 | 69.4 ± 41.4 | 0.992 |
| Visit 2 (treatment phase) | 74.3 ± 52.7 | 72.0 ± 42.2 | 0.915 |
| Visit 3 (follow-up phase) | 72.6 ± 55.7 | 72.0 ± 40.0 | 0.534 |
| Visit 4 (follow-up phase) | 78.5 ± 55.0 | 71.3 ± 37.9 | 0.806 |
| p value    | –              | 0.951      | 0.994        | –      |

Data are expressed as mean ± SD. p value is considered significant when p < 0.05. ACE, angiotensin-converting enzyme; CH, total cholesterol; CK, creatine kinase; SHBG, sex hormone-binding globulin.
influence the availability of these enzymes. However, in physiological conditions, enterohepatic recycle contributes minimally to circulating THs levels, since sulfated iodothyronines undergo rapid degradation by type 1 deiodinase (17) and deglucuronidation processes seem less important in humans than in animal models (17). This could be the reason of the lack of significant hormonal alterations in this population. However, it is not possible to exclude the presence of a “lessebo effect.” This is described as a negative patients’ expectation, related to the possibility of not receiving the “active” treatment (42). For this reason, control group patients were possibly less motivated to respect LT4 administration rules while probiotics-treated patients could have a higher motivation.

Regression analyses confirm the known correlations among TSH and BMI. Considering peripheral tissue markers of THs, both TSH and fT4 are related with CH and SHBG levels, confirming that these markers are sensible to THs (2). Moreover, the fT3/fT4 ratio showed a direct correlation to TSH in the control group at each visit, according to physiological feedback mechanism. However, this relationship was lost in the study group after 1 month of probiotic treatment. Thus, probiotics should influence the deiodinases activity, temporarily reducing the feedback. This effect could be explained considering the known anti-inflammatory property of VSL#3®, through the decrease in circulating pro-inflammatory cytokines (43). Thus, considering that deiodinases expression and activity can be modulated by cytokines (44–48), probiotics could interfere with THs deiodination. This result reinforces the hypothesis that VSL#3® is able to influence THs metabolism, although a final and significant difference in hormonal levels is not detected. Possibly, a longer treatment might be able to highlight these changes.

Even if VSL#3® is one of the most highly concentrated probiotics largely used in clinical trials, it does not contain strains expressing β-glucuronidases and sulfatases, which could directly increase the enterohepatic recycle of iodothyronines. However, contrasting data are available regarding Lactobacilli and Bifidobacteria effects on intestinal β-glucuronidase activity (29, 49). Thus, the VSL#3® modulation effect on microbiota by stimulating bacteria growth expressing β-glucuronidases and sulfatases may be only a speculation.

The main limit of this study is represented by the lack of placebo in the control group. It could limit the strength of our results, constituting a sort of “volunteer bias.” Accordingly, the dropout rate is higher in the control than in the study group (six vs. three patients), although not significant. Secondly, the difficulty to evaluate probiotics treatment compliance is another notable limit. The sachets counting expresses an estimation of therapeutic compliance, but differences in microbiota composition and enzymatic activity before and after probiotics ingestion were not evaluated. Moreover, the compliance should be measured considering dietary assessment, which was not recorded in our trial. In the literature, several beneficial effects of VSL#3® were demonstrated, even if no precise evidence about the minimum probiotics concentration required to influence microbiota is available, representing a limit in all trials using probiotics. Furthermore, despite 2 months treatment period seems to be appropriate to modify gut microbiota (50, 51), it is not possible to confirm the exact time-interval needed to obtain a significant change in microbiota composition. Thus, further trials using higher probiotics concentration for longer time should be considered. Finally, in this setting, the accuracy of the TH assay methods remains a crucial point. Commonly used immunoassays could present discrepancies in TH measurement compared to the gold standard, liquid chromatography-tandem mass spectrometry (LC-MSMS), mainly due to pharmacological interferences or pathological conditions able to modify serum transport proteins (52). Nevertheless, the use of LC-MSMS is not currently routinely available in clinical practice and our study population does not present the common conditions that may undermine the immunoassay reliability.

In conclusion, this is the first randomized controlled trial evaluating possible interactions among probiotics, LT4, therapy, and pituitary–thyroid axis. Even if these results show no significant differences in hormonal parameters between groups and among visits, a possible probiotics interaction with THs homeostasis is proposed.

These data generate the hypothesis of a “stabilization” of LT4 treatment after probiotics ingestion, suggested by the reduced dose adjustments needed in the treatment group, as well as the need of a dose reduction observed only in subjects assuming probiotics. In particular, VSL#3® seems to be able to prevent hormonal fluctuations, perhaps modulating THs enterohepatic recycle and justifying the absence of differences in serum hormonal levels. The effect, however, is limited and no major clinical consequences can be proven at this stage.

The possible probiotics role as “LT4 therapy stabilizers” could be an endearing research starting point for both endocrinologists and investigators concerned with probiotics, in order to clarify the interaction between intestinal environment and endocrine system. This association was not evaluated so far and further studies should explore the relationship between gut microbiota and THs, considering other probiotic strains or longer treatment.

ETHICS STATEMENT

The Institutional Review Board of Modena (Comitato Etico di Modena) approved the study (code 184/13, approved on 12th November 2013). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all individual participants included in the study.

AUTHOR CONTRIBUTIONS

GS collected samples, analyzed the data, and wrote the manuscript. GB conceived the study and wrote the manuscript. SV and UC collected clinical and biochemical data. LR, MS, EB, ST, MV, and TT performed laboratory assays. VR contributed writing the manuscript. MS conceived the study and contributed writing the manuscript. DS conceived the study, analyzed the data, and wrote the manuscript. All authors edited the manuscript or revised it critically for important intellectual content and approved the final draft.
**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at http://www.frontiersin.org/article/10.3389/fendo.2017.00316/full#supplementary-material.

**REFERENCES**

1. De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, et al., editors. *SourceEndotext*. South Dartmouth, MA: MDText.com, Inc. (2014).

2. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. Guidelines for the treatment of hypothyroidism: prepared by the American thyroid association task force on thyroid hormone replacement. *Thyroid* (2014) 24(12):1670–751. doi:10.1089/thy.2014.0028

3. Benvena S, Bartolone L, Pappalardo MA, Russo A, Lapa D, Giorgianni G, et al. Altered intestinal absorption of l-thyroxine caused by coffee. *Thyroid* (2008) 18(3):293–301. doi:10.1089/thy.2007.0222

4. Ianiro G, Mangiola F, Di Rienzo TA, Bibbo S, Franceschi F, Greco AV, et al. Levothyroxine absorption in health and disease, and new therapeutic perspectives. *Eur Rev Med Pharmacol Sci* (2014) 18(4):451–6.

5. Liwanpo L, Hershman JM. Conditions and drugs interfering with thyroxine adsorption of levothyroxine. *Ann Intern Med* (1992) 117(12):1010–3. doi:10.1067/aim.1992.28193.x

6. Campbell NR, Hasnain BB, Stalts H, Rao B, Wong NC. Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. *Ann Intern Med* (1992) 117(12):1010–3. doi:10.1067/aim.1992.28193.x

7. Sherman SI, Tielens ET, Ladenson PW. Sucralfate causes malabsorption of l-thyroxine. *Br J Clin Pharmacol* (2005) 60(3):337–41. doi:10.1111/j.1365-2125.2005.02433.x

8. Mersebach H, Rasmussen AK, Kirkegaard L, Feldt-Rasmussen U. Intestinal absorption of l-thyroxine by antacids and laxatives: case stories and in vitro experiments. *Pharmacol Toxicol* (1999) 84(3):107–9. doi:10.1111/j.1600-0773.1999.tb00883.x

9. Singh N, Weisler SL, Hershman JM. The acute effect of calcium carbonate with various calcium formulations. *Thyroid* (2011) 11(10):967–71. doi:10.1089/thy.2010.0725.x

10. Issa I, Moucari R. Probiotics for antibiotic-associated diarrhea: do we have a verdict? *World J Gastroenterol* (2014) 20(47):17788–95. doi:10.3748/wjg.v20.i47.17788

11. Khoder G, Menhali AA, Al-Yassir F, Karam SM. Potential role of probiotics in the management of gastric ulcer. *Exp Ther Med* (2016) 12(1):3–17. doi:10.3892/etm.2016.3293

12. Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfeld GM, Hold G, et al. The gut microbiota and host health: a new clinical frontier. *Nat Rev* (2016) 65(2):330–9. doi:10.1038/nrgastro.2015.309990

13. Goldenberg JZ, Fa, SS, Saxton JD, Martzen MR, Vandvik PO, Thorlund K, et al. Probiotics for the prevention of *Clostridium difficile*-associated diarrhea in adults and children. *Cochrane Database Syst Rev* (2013) 31(5):CD006095.

14. Dhriti S, Moucari R. Probiotics for antibiotic-associated diarrhea: do we have a verdict? *World J Gastroenterol* (2014) 20(47):17788–95. doi:10.3748/wjg.v20.i47.17788

15. Khoder G, Al-Menhali AA, Al-Yassir F, Karam SM. Potential role of probiotics in the management of gastric ulcer. *Exp Ther Med* (2016) 12(1):3–17. doi:10.3892/etm.2016.3293

16. Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfeld GM, Hold G, et al. The gut microbiota and host health: a new clinical frontier. *Nat Rev* (2016) 65(2):330–9. doi:10.1038/nrgastro.2015.309990

17. Uccello M, Malaguarnera M, Basile F, D’Agata V, Malaguarnera M, Bertino G, et al. Potential role of probiotics on colorectal cancer prevention. *BMJ Surg* (2012) 1(Suppl 1):S35. doi:10.1136/gutjnl-2015-309990

18. Griffin C. Probiotics in obstetrics and gynecology. *Aust N Z J Obstet Gynaecol* (2015) 55(3):201–9. doi:10.1111/ajo.12303

19. Baquerizo Nole KL, Yim E, Keri JE. Probiotics and prebiotics in dermatology. *J Am Acad Dermatol* (2015) 71(4):814–21. doi:10.1016/j.jaad.2014.04.050

20. Delzenne NM, Cani PD, Everard A, Neyrinck AM, Bindels LB. Gut microorganisms as promising targets for the management of type 2 diabetes. *Diabetologia* (2015) 58(10):2206–17. doi:10.1007/s00125-015-3712-7

21. Fenolla SM, Armillita GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. *World J Hepatol* (2015) 7(3):559–65. doi:10.4240/wjh.v7.i3.559

22. Hur KY, Lee MS. Gut microbiota and metabolic disorders. *Diabetes Metab J* (2015) 39(3):198–203. doi:10.4092/dmj.2015.39.3.198

23. Sun J, Buys NJ. Glucose- and glycemic factor-lowering effects of probiotics on diabetes: a meta-analysis of randomised placebo-controlled trials. *Br J Nutr* (2016) 115(7):1167–77. doi:10.1017/S0007114516000076

24. Yadav L, Lee JH, Lloyd J, Walter P, Rane SG. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. *J Biol Chem* (2013) 288(35):25088–97. doi:10.1074/jbc.M113.452516

25. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. *J Nutr* (1995) 125(6):1401–12.

26. Stojanovic M, Bojic J, Salami HA, Mikov M. The influence of intestinal tract and probiotics on the fate of orally administered drugs. *Curr Issues Mol Biol* (2014) 16:55–68.
40. Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. *Endocr Pract* (2012) 18(6):988–1026. doi:10.4158/EP12280.GL

41. Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. *JAMA* (2000) 283(21):2822–5. doi:10.1001/jama.283.21.2822

42. Mestre TA, Shah P, Marras C, Tomlinson G, Lang AE. Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses. *Neurology* (2014) 82(16):1402–9. doi:10.1212/WNL.0000000000000340

43. Rajkumar H, Mahmood N, Kumar M, Varikuti SR, Challa HR, Myakala SP. Effect of probiotic (VSL#3) and omega-3 on lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight adults: a randomized, controlled trial. *Mediators Inflamm* (2014) 2014:348959. doi:10.1155/2014/348959

44. Hosoi Y, Murakami M, Mizuma H, Ogiwara T, Imamura M, Mori M. Expression and regulation of type II iodothyronine deiodinase in cultured human skeletal muscle cells. *J Clin Endocrinol Metab* (1999) 84(9):3293–300. doi:10.1210/jcem.84.9.5969

45. Huang SA, Mulcahey MA, Crescenzi A, Chung M, Kim BW, Barnes C, et al. Transforming growth factor-beta promotes inactivation of extracellular thyroid hormones via transcriptional stimulation of type 3 iodothyronine deiodinase. *Mol Endocrinol* (2005) 19(12):3126–36. doi:10.1210/me.2005-0173

46. Kwakkel J, Wiersinga WM, Boelen A. Differential involvement of nuclear factor-kappaB and activator protein-1 pathways in the interleukin-1beta-mediated decrease of deiodinase type 1 and thyroid hormone receptor beta1 mRNA. *J Endocrinol* (2006) 189(1):37–44. doi:10.1677/joe.1.06354

47. Molnar I, Balazs C, Szegedi G, Sipka S. Inhibition of type 2,5'-deiodinase by tumor necrosis factor alpha, interleukin-6 and interferon gamma in human thyroid tissue. *Immunol Lett* (2002) 80(1):3–7. doi:10.1016/S0165-2478(01)00301-7

48. Pang XP, Hershman JM, Mirell CJ, Pekary AE. Impairment of hypothalamic-pituitary-thyroid function in rats treated with human recombinant tumor necrosis factor-alpha ( cachectin). *Endocrinology* (1989) 125(1):76–84. doi:10.1210/endo-125-1-76

49. Marteau P, Pochart P, Faurie B, Peller P, Santos L, Desjeux JF, et al. Effect of chronic ingestion of a fermented dairy product containing *Lactobacillus acidophilus* and *Bifidobacterium bifidum* on metabolic activities of the colonic flora in humans. *Am J Clin Nutr* (1990) 52(4):685–8.

50. Jafarnejad S, Saremi S, Jafarnejad F, Arab A. Effects of a multispecies probiotic mixture on glycemic control and inflammatory status in women with gestational diabetes: a randomized controlled clinical trial. *J Nutr Metab* (2016) 2016:5190846. doi:10.1155/2016/5190846

51. Kim Cha B, Min Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. *J Clin Gastroenterol* (2012) 46(3):220–7. doi:10.1097/MCG.0b013e31823712b1

52. Welsh KJ, Stolze BR, Yu X, Podsiadlo TR, Kim LS, Soldin SJ. Assessment of thyroid function in intensive care unit patients by liquid chromatography tandem mass spectrometry methods. *Clin Biochem* (2017) 50(6):318–22. doi:10.1016/j.clinbiochem.2016.11.022

**Conflict of Interest Statement:** All authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Copyright © 2017 Spaggiari, Brigante, De Vincentis, Cattini, Rolli, De Santis, Baraldi, Tagliavini, Varani, Trenti, Rochira, Simoni and Santi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.